================================================================================
Chapter 3: Drug Delivery Systems
================================================================================

[Table of Contents]

Smart pills enable precise drug delivery with controlled timing, location,
and dosage - advancing from passive monitoring to active therapeutic intervention.

--------------------------------------------------------------------------------
3.1 Controlled Release Mechanisms
--------------------------------------------------------------------------------

Time-Controlled Release:
  Erosion-Based (Zero-Order Kinetics):
    - Materials: PLGA, PCL, PLA polymers
    - Duration: Hours to weeks
    - Application: Sustained blood concentration

  Diffusion-Based (Fickian):
    - Materials: Ethylcellulose, acrylic polymers
    - Control: Membrane thickness and porosity

  Osmotic Pumps (OROS System):
    - Components: Drug core + osmotic agent, semipermeable membrane, laser-drilled orifice
    - Kinetics: Zero-order for 8-24 hours
    - Advantage: pH and motility independent

Environmentally-Triggered Release:
  pH-Triggered:
    - Enteric coatings: Eudragit L100 (pH > 6.0), S100 (pH > 7.0)
    - Targets: Duodenum pH 5-6, Jejunum 6-7, Ileum 7-8, Colon 6.5-7.5
    - Applications: Gastric protection, intestinal targeting

  Enzyme-Triggered:
    - Colonic bacteria enzymes: Azoreductase, glycosidases
    - Substrates: Azo polymers, pectin, chitosan
    - Application: Colon-specific delivery for IBD

  Temperature-Triggered:
    - PNIPAM: LCST ~32°C (adjustable)
    - Behavior: Swollen below, contracted above transition
    - Application: Fever-activated antipyretic release

Actively-Controlled Release:
  Electronic Actuation:
    - Electroporation: Voltage pulses create membrane pores
    - Iontophoresis: Electric field drives ionized drugs
    - Gold membrane dissolution: Electrochemical opening

  Magnetic Actuation:
    - Magnetic gates open/close with external magnet
    - Magnetic heating: AC field heats nanoparticles → polymer melts

  MEMS Devices:
    - Microvalves and micropumps for precise flow control
    - Piezoelectric actuators
    - Challenge: Size, power, reliability

Release Profiles:
  - Immediate: 90% < 30 minutes (rapid action)
  - Sustained: Zero-order, 8-24 hours (stable concentration)
  - Pulsatile: Intermittent bursts (circadian rhythm matching)
  - Site-specific: Release only at target location

--------------------------------------------------------------------------------
3.2 Targeted Delivery Technologies
--------------------------------------------------------------------------------

GI Tract Targeting:

Gastric Retention (2-12 hours):
  - Floating systems: Gas generation or low-density polymers (< 1 g/cm³)
  - Expanding systems: Hydrogels swell beyond pyloric size (15mm+)
  - Mucoadhesive: Carbomer, chitosan bonds to gastric mucosa
  - Applications: H. pylori treatment, GERD therapy

Small Intestine Targeting:
  - Duodenum (pH 5-6): Low-threshold enteric coating
  - Jejunum (pH 6-7): Medium-threshold enteric
  - Ileum (pH 7-8): High-pH enteric or time control (3-5 hrs)

Colon Targeting:
  - pH-triggered: Eudragit S (pH > 7.0) - but pH overlap with ileum
  - Time-dependent: 5-8 hour delay (high variability ±2 hrs)
  - Bacterially-triggered: Most specific
    * Azoreductase substrates: Azo-polymer bonds
    * Glycosidases: Pectin, guar gum, chitosan, dextran
  - Pressure-controlled: High colonic contraction pressure
  - Applications: Ulcerative colitis, Crohn's (colonic)

Multi-Targeting:
  - Layered coatings: Different dissolution pH
  - Multiparticulate: Mixed pellets with various targets
  - Sequential release: Stomach → small intestine → colon

--------------------------------------------------------------------------------
3.3 Dosage Accuracy
--------------------------------------------------------------------------------

Manufacturing Quality Control:
  - Content uniformity: USP <905>, 85-115% of label claim
  - Coating uniformity: Weight gain control, ±2-3%
  - Blending: V-blender, conical blender for API/excipient mixing

Release Control:
  - Zero-order kinetics: Osmotic systems, matrix erosion
  - First-order kinetics: Simple diffusion (decreasing rate)
  - Pulsatile: Programmed multi-dose release

Sensor-Based Adaptive Delivery:
  - Glucose-insulin: Sensor → algorithm → pump (closed-loop)
  - pH-PPI: pH < 4 detection → additional dose release
  - Inflammation-anti-inflammatory: Biomarker → increased dose
  - Challenges: Sensor accuracy, algorithm validation, safety limits

Dose Optimization:
  Pharmacokinetic Considerations:
    - Absorption: Solubility, permeability, first-pass metabolism
    - BCS Classification: Class 1-4 (solubility/permeability combinations)
    - Distribution: Volume of distribution, protein binding
    - Metabolism: Hepatic clearance, renal excretion, half-life

  Individualization:
    - Weight-based dosing: mg/kg
    - TDM: Therapeutic drug monitoring for narrow window drugs
    - Model-informed: Population PK models with Bayesian estimation
    - Smart pill-guided: GI transit time, local pH → dose adjustment

--------------------------------------------------------------------------------
3.4 Multi-Drug Systems
--------------------------------------------------------------------------------

Fixed-Dose Combinations:
  - Bi-layer tablets: Immediate + sustained release
  - Multi-layer: 3+ layers with independent profiles
  - Core-shell: Delayed core, immediate shell
  - Advantages: Improved adherence, fixed ratio
  - Challenges: Compatibility, flexibility in dose adjustment

Compartmentalized Capsules:
  - Dual-chamber: Separated by dissolvable septum
  - Multi-reservoir: Individual MEMS-controlled compartments
  - Sequential delivery: Antiemetic → (delay) → chemotherapy

Synergistic Combinations:
  - Antibiotics: Amoxicillin + clavulanic acid (β-lactamase inhibitor)
  - Cardiovascular: ARB + calcium channel blocker
  - Cancer: Chemotherapy + immunotherapy
  - Pain: Opioid + acetaminophen

Chronotherapy:
  - Circadian rhythm matching: Blood pressure surge timing
  - Pulsatile delivery: Bedtime ingestion, 4-6 hr delay → morning release
  - Examples: Asthma (early morning), arthritis (morning stiffness)

Tailored Polypharmacy:
  - Concept: Personalized multi-drug capsule
  - Process: Patient Rx → 3D printing/modular assembly → custom capsule
  - Benefits: 1-3 doses/day instead of 15+, reduced errors
  - Status: Research/pilot stage

Key Principle: Multi-drug systems require thorough evaluation of drug-drug
compatibility, stability, pharmacokinetic interactions, and regulatory approval
for each specific combination.

[Next: Chapter 4]
[Table of Contents]

================================================================================